Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO® tablets



The U.S. Food and Drug Administration ... | April 11, 2023

Related Keywords

United States ,American ,Eric Hughes ,Teva Pharmaceuticals ,Teva Pharmaceutical Industries Ltd ,Drug Administration ,American Academy Of Neurology ,Teva Pharmaceutical Industries ,American Academy ,Annual Meeting ,Executive Vice President ,Chief Medical Officer ,Chorea Severity Change Over Time ,Huntington Disease ,Huntington Disease Stage ,Sunday April ,Bioequivalence Comparison ,Steady State ,Approved Twice Daily Tablet Formulation ,Dose Proportionality ,Three Dose Strengths ,Clinical Dose Range ,Real World Effectiveness ,Antipsychotic Drugs ,Baseline Characteristics ,Treatment Patterns ,Global Huntington Disease Population Stratified ,Chorea Severity ,Wednesday April ,Fremanezumab Earlier ,Treatment Cycle ,Cost Savings ,Preventive Treatment ,Second Interim Analysis ,Claims Based Analysis ,Migraine Related Healthcare Resource ,Acute Medication Use ,Mab Targeting ,Migraine Prevention ,Interim Analysis ,Tardive Dyskinesia ,Chorea Associated ,Release Tablets ,Adverse Events ,Malignant Syndrome ,Melanin Containing Tissues ,Adverse Reactions ,Prescribing Information ,Pharmaceutical Industries ,Private Securities Litigation Reform Act ,Annual Report ,Term Deutetrabenazine Treatment ,Sustained Benefits ,Open Label Extension ,Teva Pharmaceutical Industries Limited Stock Exchange ,News ,Information ,Press Release ,Nose ,Proportionality ,End ,Bioequivalence ,Studies ,Emonstrate ,Austedo ,Dr ,Us ,Therapeutically ,Equivalent ,O ,Wood ,Drug ,Dministration Teva Us8816242098 ,